Aclaris Therapeutics
ACRS
3.38
-0.02
-0.71%
Aclaris Therapeutics
US · ACRS
#3750 by market cap
Listed 2015
3.38
-0.02
-0.71%
Live - 5344 symbols - heartbeat 225s ago
· 2026-10-08 10:00
Pre-market
3.44
+1.11%
After-hours
3.46
+1.76%
Overnight
3.39
-0.29%
- Market cap
- 496.94M
- P/E (TTM)i
- -5.82
- P/Bi
- 3.99
- EPSi
- -0.53
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on ACRS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -4.22, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -58.19% YoY
Margins
- Gross margin
- 6.93%
- Operating margin
- -946.52%
- Net margin
- -829.58%
Key ratios & quality
- Altman Z-Scorei
- -4.22
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.15M | 4.23M | 6.48M | 6.76M | 29.75M | 31.25M | 18.72M | 7.83M |
| Gross profit | 1.82M | 172.00K | 1.35M | 2.05M | 17.79M | 13.17M | 3.26M | 542.00K |
| Selling & admin expenses | 25.76M | 27.83M | 20.53M | 23.62M | 25.13M | 31.10M | 22.20M | 21.97M |
| Research & development | 60.84M | 64.17M | 29.34M | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M |
| Operating profit | -84.78M | -91.82M | -48.52M | -65.38M | -85.15M | -116.31M | -52.53M | -74.08M |
| Pretax profit | -82.10M | -113.54M | -51.34M | -90.87M | -86.91M | -88.85M | -132.07M | -64.92M |
| Tax | 0 | 0 | -182.00K | 0 | 0 | -367.00K | -- | -- |
| Net profit | -132.74M | -161.35M | -51.02M | -90.87M | -86.91M | -88.48M | -132.07M | -64.92M |
| Basic EPS | -4 | -4 | -1 | -2 | -1 | -1 | -2 | -1 |
| Diluted EPS | -4.03 | -3.90 | -1.20 | -1.60 | -1.33 | -1.27 | -1.71 | -0.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.46M | 1.78M | 3.30M | 1.30M | 2.00M | 1.63M |
| Gross profit | -61.00K | -73.00K | 850.00K | -174.00K | 208.00K | 176.00K |
| Selling & admin expenses | 6.14M | 5.39M | 4.87M | 5.58M | 6.74M | 6.05M |
| Research & development | 11.58M | 11.45M | 13.03M | 16.58M | 15.66M | 18.07M |
| Operating profit | -17.78M | -16.91M | -17.05M | -22.33M | -22.19M | -23.94M |
| Pretax profit | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M | -21.51M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -15.09M | -15.43M | -14.61M | -19.80M | -19.82M | -21.51M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.12 | -0.13 | -0.12 | -0.16 | -0.15 | -0.15 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 179.50M | 83.80M | 57.49M | 205.03M | 231.55M | 128.86M | 125.95M | 96.32M |
| Cash & ST investments | 167.97M | 73.27M | 54.13M | 191.41M | 217.57M | 119.11M | 113.59M | 90.75M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 275.57M | 98.30M | 70.78M | 251.21M | 254.60M | 197.41M | 220.33M | 160.46M |
| Total current liabilities | 27.34M | 22.43M | 14.87M | 22.93M | 21.94M | 30.95M | 31.60M | 28.65M |
| Short-term debt | 142.00K | 637.00K | 603.00K | 693.00K | 684.00K | -- | -- | -- |
| Long-term debt | 29.91M | -- | 10.65M | -- | -- | -- | -- | -- |
| Total liabilities | 60,442,000.00 | 28,385,000.00 | 33,134,000.00 | 53,870,000.00 | 56,975,000.00 | 40,226,000.00 | 64,773,000.00 | 57,378,000.00 |
| Total equity | 215.12M | 69.91M | 37.65M | 197.34M | 197.62M | 157.18M | 155.55M | 103.08M |
| Retained earnings | -292.17M | -453.53M | -504.54M | -595.41M | -682.32M | -770.80M | -902.86M | -967.78M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 108.79M | 104.20M | 100.59M | 96.32M | 110.23M | 97.77M |
| Cash & ST investments | 105.31M | 99.81M | 95.91M | 90.75M | 105.42M | 91.56M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 198.09M | 189.15M | 175.53M | 160.46M | 198.72M | 179.69M |
| Total current liabilities | 21.51M | 26.84M | 25.63M | 28.65M | 27.37M | 28.24M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 54,028,000.00 | 57,408,000.00 | 55,434,000.00 | 57,378,000.00 | 55,071,000.00 | 55,112,000.00 |
| Total equity | 144.07M | 131.74M | 120.10M | 103.08M | 143.65M | 124.58M |
| Retained earnings | -917.95M | -933.38M | -947.99M | -967.78M | -987.61M | -1.01B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -100.81M | -96.45M | -38.63M | -52.13M | -67.57M | -78.33M | -20.08M | -47.11M |
| Depreciation & amortization | 1.88M | 6.41M | 1.32M | 923.00K | 797.00K | 863.00K | 807.00K | 454.00K |
| Free cash flow | -102.17M | -98.06M | -39.09M | -52.44M | -68.17M | -79.63M | -56.01M | -47.22M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 100.21M | 0 | 7.74M | 238.20M | 72.74M | 26.71M | 74.91M | 0 |
| Ending cash balance | 57.02M | 35.94M | 22.06M | 27.35M | 45.28M | 39.88M | 24.57M | 19.96M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.06M | -9.99M | -10.93M | -13.13M | -18.15M | -19.85M |
| Depreciation & amortization | 128.00K | 114.00K | 110.00K | 102.00K | 102.00K | 107.00K |
| Free cash flow | -13.93M | -9.18M | -10.96M | -13.16M | -18.16M | -19.91M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 57.88M | 0 |
| Ending cash balance | 30.36M | 25.40M | 25.26M | 19.96M | 28.66M | 19.17M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -60.28 | -113.22 | -94.86 | -77.33 | -44.01 | -49.88 | -84.46 | -50.20 |
| ROA %i | -51.14 | -86.32 | -60.34 | -56.44 | -34.36 | -39.15 | -63.23 | -34.10 |
| ROIC %i | -52.99 | -112.73 | -78.42 | -76.91 | -43.86 | -49.72 | -84.46 | -56.11 |
| 5-year avg ROE %i | -- | -61.87 | -67.95 | -76.08 | -77.94 | -75.86 | -70.11 | -61.18 |
| EBIT margin %i | -1,327.06 | -2,189.59 | -785.44 | -967.08 | -286.21 | -372.22 | -280.59 | -946.52 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.56 | 3.74 | 3.87 | 8.94 | 10.55 | 4.16 | 3.99 | 3.36 |
| Quick ratioi | 6.16 | 3.30 | 3.69 | 8.37 | 9.94 | 3.86 | 3.60 | 3.17 |
| Debt / assetsi | 10.91 | 0.65 | 15.90 | 0.28 | 0.27 | -- | -- | -- |
| LT debt / equityi | 13.91 | -- | 28.29 | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 56.75 | 3.20 | 91.64 | 68.93 | 40.42 | -35.93 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -91.03 | -101.41 | -113.23 | -50.20 | -48.42 | -59.10 |
| ROA %i | -69.97 | -76.90 | -79.17 | -34.10 | -35.11 | -41.07 |
| ROIC %i | -91.03 | -101.41 | -113.23 | -56.11 | -53.28 | -64.35 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -304.78 | -348.04 | -418.06 | -946.52 | -938.01 | -1,040.43 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.06 | 3.88 | 3.92 | 3.36 | 4.03 | 3.46 |
| Quick ratioi | 4.91 | 3.73 | 3.92 | 3.17 | 3.85 | 3.24 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Identifying and developing innovative therapies to address significant unmet needs for100.00%
Quote time 2026-10-08 10:00:33 · For reference only, not investment advice and not tailored to your situation.